ASMB
- Assembly Biosciences, Inc.
()
Overview
Company Summary
Assembly Biosciences, Inc. is a biotechnology company that focuses on the development of innovative therapies for viral infections of the liver. Their primary area of expertise lies in developing a new class of oral antiviral therapeutics called Assembly Activators.
Assembly Biosciences has a profound interest in addressing viral hepatitis, specifically hepatitis B virus (HBV) and hepatitis C virus (HCV), which affect millions of people worldwide. Their aim is to improve upon existing treatment options for these viral infections, which often have limitations in terms of efficacy and adverse effects.
The company's key technology platform, known as the core protein allosteric modulators (CpAMs), is the foundation for their antiviral drug development. CpAMs aim to inhibit viral replication and reduce viral load by targeting the viral core protein, a vital component of the virus's lifecycle. By targeting this critical protein, Assembly Biosciences hopes to develop therapies that can effectively control and potentially cure chronic viral infections.
Aside from their core protein allosteric modulators, Assembly Biosciences also has a comprehensive drug discovery platform that incorporates advanced techniques such as medicinal chemistry, computational biology, and structural biology. These tools aid in identifying and optimizing potential drug candidates to advance through preclinical and clinical development.
Assembly Biosciences seeks to make a meaningful impact on patients' lives by developing safe and effective therapies for viral infections of the liver. Through their research and development efforts, they aspire to improve treatment outcomes, reduce the burden of chronic viral infections, and ultimately eradicate these diseases.